CHEK2 and prostate cancer: Truncating CHEK2 variants have also been shown to confer a slightly increased risk for gastric cancer, kidney cancer, sarcoma, prostate cancer [10], and colorectal cancer [11], with the relative risk for the latter estimated to be 1.88 [52].